CN103175964B - 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 - Google Patents
神经元特异性烯醇化酶含量检测试剂盒及其制备方法 Download PDFInfo
- Publication number
- CN103175964B CN103175964B CN201310055143.8A CN201310055143A CN103175964B CN 103175964 B CN103175964 B CN 103175964B CN 201310055143 A CN201310055143 A CN 201310055143A CN 103175964 B CN103175964 B CN 103175964B
- Authority
- CN
- China
- Prior art keywords
- reagent
- latex
- neuronspecific enolase
- antibody
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 73
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 title claims abstract description 65
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title abstract description 26
- 239000004816 latex Substances 0.000 claims abstract description 116
- 229920000126 latex Polymers 0.000 claims abstract description 116
- 239000002245 particle Substances 0.000 claims abstract description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- 238000001514 detection method Methods 0.000 claims abstract description 51
- 239000006177 biological buffer Substances 0.000 claims abstract description 24
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 22
- 239000000375 suspending agent Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- -1 antiseptic Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 55
- 239000012153 distilled water Substances 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 32
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 25
- 230000009514 concussion Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims description 11
- 230000001235 sensitizing effect Effects 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 6
- 239000012901 Milli-Q water Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000008366 buffered solution Substances 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000008118 PEG 6000 Substances 0.000 claims description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical class CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000005036 nerve Anatomy 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000012530 fluid Substances 0.000 description 16
- 238000013016 damping Methods 0.000 description 15
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000004321 preservation Methods 0.000 description 10
- 206010041067 Small cell lung cancer Diseases 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 102000011690 Adiponectin Human genes 0.000 description 6
- 108010076365 Adiponectin Proteins 0.000 description 6
- 239000007993 MOPS buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 description 6
- CCMKPCBRNXKTKV-UHFFFAOYSA-N 1-hydroxy-5-sulfanylidenepyrrolidin-2-one Chemical compound ON1C(=O)CCC1=S CCMKPCBRNXKTKV-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001718 carbodiimides Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310055143.8A CN103175964B (zh) | 2013-02-21 | 2013-02-21 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310055143.8A CN103175964B (zh) | 2013-02-21 | 2013-02-21 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103175964A CN103175964A (zh) | 2013-06-26 |
CN103175964B true CN103175964B (zh) | 2015-08-26 |
Family
ID=48635963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310055143.8A Active CN103175964B (zh) | 2013-02-21 | 2013-02-21 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103175964B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103529225B (zh) * | 2013-11-04 | 2016-01-13 | 武汉华美生物工程有限公司 | 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
CN108053866B (zh) * | 2017-12-12 | 2020-09-25 | 迈克医疗电子有限公司 | 工作曲线的传递方法、装置、设备和存储介质 |
CN110736837B (zh) * | 2019-09-17 | 2023-04-07 | 北京九强生物技术股份有限公司 | 神经元特异性烯醇化酶的胶乳免疫比浊检测试剂盒 |
CN112730827A (zh) * | 2020-12-11 | 2021-04-30 | 常州爱复康生物科技有限公司 | 一种新型冠状病毒抗体检测试剂盒及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101813700A (zh) * | 2010-03-31 | 2010-08-25 | 浙江伊利康生物技术有限公司 | 一种纳米微球免疫比浊法检测β2-微球蛋白试剂盒 |
CN102253217A (zh) * | 2011-04-07 | 2011-11-23 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN102353770A (zh) * | 2011-06-03 | 2012-02-15 | 宁波美康生物科技有限公司 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
CN102419372A (zh) * | 2011-08-16 | 2012-04-18 | 内蒙古科慧生物科技有限责任公司 | 神经元特异性烯醇化酶(nse)定量测定试剂盒及其检测方法 |
CN102662061A (zh) * | 2012-04-17 | 2012-09-12 | 北京九强生物技术股份有限公司 | 胶乳增强免疫比浊法测定人甲胎蛋白含量的试剂盒 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4488460B2 (ja) * | 2000-08-28 | 2010-06-23 | シスメックス株式会社 | 免疫分析方法および試薬 |
GB0914535D0 (en) * | 2009-08-19 | 2009-09-30 | Binding Site Group The Ltd | Prognosis assay |
-
2013
- 2013-02-21 CN CN201310055143.8A patent/CN103175964B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101813700A (zh) * | 2010-03-31 | 2010-08-25 | 浙江伊利康生物技术有限公司 | 一种纳米微球免疫比浊法检测β2-微球蛋白试剂盒 |
CN102253217A (zh) * | 2011-04-07 | 2011-11-23 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN102353770A (zh) * | 2011-06-03 | 2012-02-15 | 宁波美康生物科技有限公司 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
CN102419372A (zh) * | 2011-08-16 | 2012-04-18 | 内蒙古科慧生物科技有限责任公司 | 神经元特异性烯醇化酶(nse)定量测定试剂盒及其检测方法 |
CN102662061A (zh) * | 2012-04-17 | 2012-09-12 | 北京九强生物技术股份有限公司 | 胶乳增强免疫比浊法测定人甲胎蛋白含量的试剂盒 |
Non-Patent Citations (2)
Title |
---|
血清肿瘤标志物联合检测在肺癌诊断中的应用;张伟等;《天津医科大学学报》;20031231;第9卷(第2期);209-211 * |
血清肿瘤标志物联合检测对肺癌诊断的临床价值;陈虎云等;《实用预防医学》;20070831;第14卷(第4期);1229-1230 * |
Also Published As
Publication number | Publication date |
---|---|
CN103175964A (zh) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103123319B (zh) | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 | |
He et al. | Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity | |
CN104237522A (zh) | 脂联素含量检测试剂盒及其制备方法 | |
CN103175964B (zh) | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 | |
CN102253217B (zh) | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN111337691B (zh) | 一种灵敏、稳定的血清降钙素原测定试剂盒及其制备方法和应用 | |
CN103558400A (zh) | 一种降钙素原乳胶增强免疫比浊法检测试剂盒 | |
CN104198723A (zh) | 一种基于氨基酸间臂的ngal快速检测试剂盒 | |
CN110736837B (zh) | 神经元特异性烯醇化酶的胶乳免疫比浊检测试剂盒 | |
CN112730839B (zh) | 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒 | |
CN107942067A (zh) | 抗环瓜氨酸肽抗体测定试剂盒 | |
CN103823070A (zh) | 一种高灵敏度的胱抑素c测定试剂盒 | |
CN103323596B (zh) | 髓过氧化物酶含量检测试剂盒及其制备方法 | |
CN111044724B (zh) | 一种胸苷激酶1磁微粒化学发光测定试剂盒及其制备方法 | |
CN104535770A (zh) | 一种复合抗体的肌红蛋白测定试剂盒 | |
CN103308681B (zh) | 胰蛋白酶原-2检测试剂盒及制备方法 | |
CN111089958A (zh) | 一种基于葡聚糖信号放大的p16INK4a化学发光试剂盒 | |
CN104614528A (zh) | 一种线性范围更宽的视黄醇结合蛋白测定试剂盒 | |
CN110806487A (zh) | 一种用于人肝素结合蛋白检测的试剂盒及其制备方法 | |
CN111057150A (zh) | 一种乳胶微球及其应用以及糖化血红蛋白检测试剂盒 | |
CN106771152A (zh) | 一种快速检测钙卫蛋白的试剂盒 | |
CN107942068B (zh) | β2-微球蛋白测定试剂盒 | |
CN112255421B (zh) | 一种脂蛋白a检测试剂盒及检测方法 | |
Kumar et al. | High levels of inactive thymidine kinase 1 polypeptide detected in sera from dogs with solid tumours by immunoaffinity methods: implications for in vitro diagnostics | |
CN106290871A (zh) | 一种用于检测血清中sod的胶乳增强免疫比浊法试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Neuron specific enolase content detection kit and preparation method thereof Effective date of registration: 20181227 Granted publication date: 20150826 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: CUSABIO Biotech Co., Ltd. Registration number: 2018420000079 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201228 Granted publication date: 20150826 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: CUSABIO BIOTECH Co.,Ltd. Registration number: 2018420000079 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Neuron specific enolase assay kit and its preparation Effective date of registration: 20210128 Granted publication date: 20150826 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: CUSABIO BIOTECH Co.,Ltd. Registration number: Y2021420000005 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210601 Granted publication date: 20150826 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: CUSABIO BIOTECH Co.,Ltd. Registration number: Y2021420000005 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |